View More Recent Stories

May 18, 2022 08:15AM Evolus Celebrates Third Anniversary of the Launch of Jeuveau® in the United States
May 11, 2022 08:45AM Evolus to Participate in the H.C. Wainwright Global Investment Conference
May 10, 2022 04:05PM Evolus Reports First Quarter 2022 Results and Provides Business Update
Apr 26, 2022 08:45AM Evolus to Report First Quarter 2022 Results and Provide Business Update
Mar 31, 2022 08:15AM Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®
Mar 8, 2022 08:45AM Evolus to Participate in the Barclays Global Healthcare Conference
Mar 3, 2022 04:05PM Evolus (EOLS) Announces CFO Retirement
Mar 3, 2022 04:05PM Evolus Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update
Mar 3, 2022 04:05PM Evolus Announces Retirement of Chief Financial Officer Lauren Silvernail
Mar 1, 2022 08:45AM Evolus Names Christos Monovoukas Senior Vice President of Corporate Development
Feb 17, 2022 08:45AM Evolus to Report Fourth Quarter and Year End 2021 Results and Provide Business Update
Feb 8, 2022 08:47AM Evolus (EOLS) Announces Acceptance of Submission in Australia
Feb 8, 2022 08:45AM Evolus Receives Acceptance of Submission in Australia, a Pivotal Step in Approval Process for Nuceiva®
Feb 2, 2022 09:15AM Evolus to Participate in the Virtual 11th Annual SVB Leerink Global Healthcare Conference
Jan 26, 2022 08:45AM Evolus (EOLS) Reports Prelim Q4 Revenue of $34.7M
Jan 26, 2022 08:45AM Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Net Revenue and Provides 2022 Guidance
Feb 19, 2021 09:16AM AbbVie (ABBV), Evolus (EOLS), and Medytox Announce Resolution of Intellectual Property Litigation
Feb 19, 2021 09:15AM AbbVie, Evolus, and Medytox Announce Resolution of Intellectual Property Litigation
Feb 22, 2018 11:20AM Evolus, Inc. (Nasdaq: EOLS) to Ring The Nasdaq Stock Market Closing Bell
View More Recent Stories